Andrew Vo1,2, Ken N Seergobin1, Sarah A Morrow3, Penny A MacDonald4,5,6. 1. Brain and Mind Institute, University of Western Ontario, London, ON, Canada. 2. Department of Psychology, University of Western Ontario, London, ON, Canada. 3. Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada. 4. Brain and Mind Institute, University of Western Ontario, London, ON, Canada. penny.macdonald@gmail.com. 5. Department of Psychology, University of Western Ontario, London, ON, Canada. penny.macdonald@gmail.com. 6. Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada. penny.macdonald@gmail.com.
Abstract
RATIONALE: Dopaminergic therapy improves some cognitive functions and worsens others in patients with Parkinson's disease (PD). These paradoxical effects are explained by the dopamine overdose hypothesis, which proposes that effects of dopaminergic therapy on a cognitive function is determined by the baseline dopamine levels in brain regions mediating that function. OBJECTIVES: We directly tested this prevalent hypothesis, evaluating the effects of levodopa on stimulus-reward learning in healthy young adults, who presumably have optimal baseline dopamine levels and dopamine regulation. METHODS:Twenty-six healthy, young adults completed aprobabilistic reversal learning task in a randomized, double-blind, placebo-controlled, crossover design. Participants completed one session on levodopa 100 mg/carbidopa 25 mg and another session on placebo. RESULTS: We found that levodopa impaired reversal learning relative to placebo. Further analyses revealed that levodopa impaired learning from both punishment and reward. CONCLUSIONS:Exogenous dopamine impairs stimulus-reward learning, independent of PD pathology and prior to sensitization through repeated exposure, in healthy adults with normal cognition and baseline dopamine function. Our findings support the dopamine overdose hypothesis and caution clinicians about detrimental effects of levodopa in all clinical populations (e.g., early PD, restless leg syndrome) regardless of baseline cognitive and dopaminergic system function.
RCT Entities:
RATIONALE: Dopaminergic therapy improves some cognitive functions and worsens others in patients with Parkinson's disease (PD). These paradoxical effects are explained by the dopamineoverdose hypothesis, which proposes that effects of dopaminergic therapy on a cognitive function is determined by the baseline dopamine levels in brain regions mediating that function. OBJECTIVES: We directly tested this prevalent hypothesis, evaluating the effects of levodopa on stimulus-reward learning in healthy young adults, who presumably have optimal baseline dopamine levels and dopamine regulation. METHODS: Twenty-six healthy, young adults completed a probabilistic reversal learning task in a randomized, double-blind, placebo-controlled, crossover design. Participants completed one session on levodopa 100 mg/carbidopa 25 mg and another session on placebo. RESULTS: We found that levodopa impaired reversal learning relative to placebo. Further analyses revealed that levodopa impaired learning from both punishment and reward. CONCLUSIONS: Exogenous dopamine impairs stimulus-reward learning, independent of PD pathology and prior to sensitization through repeated exposure, in healthy adults with normal cognition and baseline dopamine function. Our findings support the dopamineoverdose hypothesis and caution clinicians about detrimental effects of levodopa in all clinical populations (e.g., early PD, restless leg syndrome) regardless of baseline cognitive and dopaminergic system function.
Authors: Alex A MacDonald; Oury Monchi; Ken N Seergobin; Hooman Ganjavi; Ruzbeh Tamjeedi; Penny A MacDonald Journal: Mov Disord Date: 2012-11-19 Impact factor: 10.338
Authors: Penny A MacDonald; Alex A MacDonald; Ken N Seergobin; Ruzbeh Tamjeedi; Hooman Ganjavi; Jean-Sebastien Provost; Oury Monchi Journal: Brain Date: 2011-05 Impact factor: 13.501
Authors: Marieke E van der Schaaf; Martine R van Schouwenburg; Dirk E M Geurts; Arnt F A Schellekens; Jan K Buitelaar; Robbert Jan Verkes; Roshan Cools Journal: Cereb Cortex Date: 2012-11-25 Impact factor: 5.357
Authors: Roshan Cools; Simon J G Lewis; Luke Clark; Roger A Barker; Trevor W Robbins Journal: Neuropsychopharmacology Date: 2006-07-12 Impact factor: 7.853
Authors: Heather E Webber; Paula Lopez-Gamundi; Sydney N Stamatovich; Harriet de Wit; Margaret C Wardle Journal: Neurosci Biobehav Rev Date: 2020-11-14 Impact factor: 8.989
Authors: Anthony J Angwin; Wayne J Wilson; Wendy L Arnott; Annabelle Signorini; Robert J Barry; David A Copland Journal: Sci Rep Date: 2017-10-12 Impact factor: 4.379
Authors: Cornelius J H M Klemann; Helena Xicoy; Geert Poelmans; Bas R Bloem; Gerard J M Martens; Jasper E Visser Journal: Mol Neurobiol Date: 2017-10-10 Impact factor: 5.590
Authors: Brian D Robertson; Abdullah S Al Jaja; Alex A MacDonald; Nole M Hiebert; Ruzbeh Tamjeedi; Ken N Seergobin; Ute I Schwarz; Richard B Kim; Penny A MacDonald Journal: Front Neurol Date: 2018-08-21 Impact factor: 4.003